GleamWall
中文EN

AMRN AMARIN CORP PLC\UK

Pharmaceutical Preparations · Nasdaq · SEC CIK 897448 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-22.3%
TTM net income YoY77.8%
TTM EPS YoY81.0%
Revenue 3-yr CAGR-18.3%
Net income 3-yr CAGR—

Margins

Gross margin40.9%
Operating margin-18.2%
Net margin-10.9%
FCF margin—
EBITDA margin—

Returns

ROE-4.2%
ROA-3.0%
ROIC (approx.)-8.1%
Asset turnover0.27x

Leverage & solvency

Liabilities / assets29.9%
Debt / equity0.00x
Current ratio3.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$39.55M$42.21M$45.13M$49.22M$49.67M$72.74M$42.02M$62.31M
Gross profit$16.18M$14.99M$17.77M$23.17M$22.21M$50.36M$25.13M-$9.57M
R&D expense$4.21M$4.77M$4.67M$5.37M$4.21M$4.92M$5.31M$5.99M
SG&A expense$14.34M$22.19M$21.11M$20.06M$19.70M$38.67M$36.57M$36.97M
Operating income-$2.36M-$12.01M-$11.33M-$6.33M-$11.10M-$15.98M-$16.75M-$52.52M
Pretax income$315,000-$7.87M-$8.72M-$852,000-$8.12M-$13.45M-$13.63M-$49.91M
Income tax$70,000-$219,000$1.79M$372,000-$377,000$689,000$2.07M-$1.29M
Net income$245,000-$7.65M-$10.51M-$1.22M-$7.74M-$14.14M-$15.70M-$48.62M
EPS (basic)0.00-0.02-0.03—-0.02-0.03-0.04—
EPS (diluted)0.00-0.02-0.03—-0.02-0.03-0.04—
Weighted avg. shares (diluted)427.86M416.44M419.05M—415.53M414.48M413.42M—
Balance sheet
Cash & equivalents$156.51M$143.56M$131.06M$134.66M$122.80M$147.88M$119.52M$121.04M
Short-term investments$166.87M$171.09M$176.76M$167.93M$163.78M$150.83M$162.26M$173.18M
Receivables$111.57M$92.92M$108.05M$126.83M$127.31M$119.13M$106.73M$122.28M
Inventory$158.85M$164.07M$183.59M$195.91M$184.70M$171.24M$159.49M$166.05M
Current assets$612.88M$602.76M$626.02M$649.88M$628.33M$606.82M$573.06M$595.40M
PP&E, net———$12,000$13,000$14,000$15,000$16,000
Intangibles$11.46M$12.09M$12.73M$13.37M$14.07M$14.93M$15.66M$16.39M
Total assets$634.08M$624.36M$645.76M$670.77M$659.81M$670.13M$655.68M$685.35M
Current liabilities$175.14M$164.19M$179.64M$194.46M$182.23M$185.95M$162.41M$179.95M
Total liabilities$189.67M$180.75M$196.35M$211.49M$200.92M$205.20M$181.99M$199.17M
Shareholders' equity$444.41M$443.62M$449.41M$459.28M$458.89M$464.92M$473.69M$486.18M
Shares outstanding421.63M420.04M419.59M416.21M415.97M415.40M414.37M411.58M
Cash flow statement
Operating cash flow$9.22M$6.60M$6.39M$15.28M-$12.70M$16.61M-$12.46M-$13.31M
Investing cash flow$4.56M$6.14M-$8.30M-$3.52M-$12.13M$12.41M$12.06M-$22.84M
Financing cash flow-$826,000-$247,000-$1.69M-$4,000-$248,000-$663,000-$1.12M$17,000
Stock-based compensation$1.38M$2.10M$2.33M$1.61M$1.96M$6.04M$4.33M$3.40M

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.